Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00326248 | Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women | PHASE3 | COMPLETED | 482 | — | — | Mar 1, 2006 | Jul 1, 2006 | Oct 26, 2016 | 58 | United States, Canada +9 |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GW679769 (casopitant) | DRUG | - |
Inclusion criteria: * History of PONV and/or motion sickness. * Have not smoked for the last 6 months. * Having certain types of abdominal, breast or shoulder surgeries. Exclusion criteria: * Pregnant or breastfeeding. * Taking certain medications. * Have certain pre-existing medical conditions.